DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).

Trial Details

NCT ID

NCT04106115

Phase

PHASE1 / PHASE2

Sponsor

University College, London

Status

RECRUITING

Cancer Type

Non-Muscle-Invasive Bladder Cancer

Interventions

Durvalumab
S-488210/S-488211

Locations (sample)

Cambridge, United Kingdom|52.2,0.11667
London, United Kingdom|51.50853,-0.12574
London, United Kingdom|51.50853,-0.12574
London, United Kingdom|51.50853,-0.12574
London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

Histologically proven high risk non-muscle invasive bladder cancer (NMIBC)
Adequate archival tissue sample available for histological assessment (date sample taken must be within 6 months of planned start of treatment)
Predominant histologic component (\> 50%) must be urothelial (transitional cell) carcinoma
Bacillus Calmette-Guerin (BCG) unresponsive disease or are intolerant of BCG therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →